Aquestive Therapeutics Inc (AQST) Actualités

Form 8-K - Current report

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Reaffirms New Drug Application (NDA) first quarter 2025 submission guidanceConfirms no additional adult...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WAQRREN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine...

Form 8-K - Current report

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College

Initial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or...

Form 8-K - Current report

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film

Completed OAS challenge study meets both primary and secondary endpointsDemonstrates rapid resolution of...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors